UCL School of Pharmacy
- About the School
- Study Here
- Master of Pharmacy (MPharm)
- MSc in Clinical Pharmacy, International Practice and Policy
- MSc in Drug Delivery
- MSc in Drug Discovery and Development
- MSc in Drug Discovery and Pharma Management
- MSc in Pharmacognosy
- MSc Experimental Pharmacology and Therapeutics
- Master of Research (MRes)
- Research Areas
- How to apply
- Entry requirements
- Tuition Fees
- PhD Studentships
- Next-generation sequencing in inhibitory synaptic disorders
- Nanoparticle self-association from inhaled microparticles
- Understanding the role of Ca2+ currents in influencing neuronal activity in entorhinal cortical neurons.
- Understanding the mechanisms of hyposmia in a novel model of early stage Parkinson's Disease (ESPD) and its reversal by exendin-4
- Structure-function studies of defective excitatory and inhibitory transmission in neurological disease
- New methods for exquisite control and quantification of amorphous pharmaceuticals
- High-throughput discovery of novel nanoparticulate vaccine adjuvants for humans
- Development of novel formulations to improve skin health
- The Development of Electrospun Nanofibrous Matrices for the Oral Delivery of Poorly Water Soluble Therapeutic Agents
- Scholarships & funding
- Pharmacy Practice (PG Dip/MSc)
- Certificate in Medicines Management for Pharmacy Technicians
- Research Themes
- News Archive
- Student Life
- International students
- Library and Services
- Research Departments
- Work Here
- Contact Us
- UCL School of Pharmacy News
Next-generation sequencing in inhibitory synaptic disorders
Lead Supervisor: Professor Robert J Harvey (UCL School of Pharmacy)
Industrial Collaborator: Center for Genomics and Transcriptomics (CeGaT) GmbH
Defects in human glycinergic neurotransmission result in startle disease or hyperekplexia. This neurological disorder affects newborn children and is characterised by noise- or touch-induced seizures, which result in muscle stiffness and neonatal apnoea episodes. Although rare, this disorder can have serious consequences, including brain damage and/or sudden infant death. Ongoing work confirms that the major cause of this disorder is mutations in the postsynaptic glycine receptor (GlyR) α1 subunit gene (GLRA1), with a minor number of mutations found in the GlyR β subunit gene (GLRB). Although mutations in SLC6A5, encoding the presynaptic glycine transporter GlyT2,are a second major cause of this disorder (Carta et al 2012) several indviduals do not have mutations in any of these genes.This project aims to identify rare sequence variants associated with startle disease/hyperekplexia, epilepsy and neuromuscular disorders, using array CGH and exome sequencing approaches (Lemke et al 2012). We will also develop custom functional assays to directly test the pathogenicity of rare sequence variants in cellular assays, e.g. for ion-channel trafficking/function.
1. Carta et al 2012, Mutations in the GlyT2 gene
(SLC6A5) are a second major cause of startle disease. J Biol Chem, in press.
Lemke et al (2012) Targeted next generation sequencing as a diagnostic tool in
epileptic disorders. Epilepsia, in press.
A first or upper second class honours degree in biology, biochemistry, genetics or neuroscience with a preference for postgraduate experience of molecular biology/genetics / bioinformatics.
This studentship is only open to students with Home and EU fee status.
Main Methods and Technologies to be employed
The student will have the unique opportunity to receive training in next-generation sequencing, bioinformatics and structure-function assays. The studentship is a joint project between Professor Harvey's laboratory in the Department of Pharmacology at the UCL School of Pharmacy and the Center for Genomics and Transcriptomics (CeGaT: http://www.cegat.de/) in Tübingen, Germany. CeGaT is a world-leader in the use of next-generation sequencing methods in clinical applications, using Applied Biosystems SOLiD 5500xl and Life Technologies Ion Torrent personal genome analyzer instruments - the most accurate and high-throughput sequencing platforms available.
Further details about the project may be obtained from:
Tel: (44) 207 753 5930
UCL School of Pharmacy
University of London
29/39 Brunswick Square
London WC1N 1AX
Tel: +44 (0) 207 5831
Please submit the following supporting documents with your application form:
Transcripts: University examination transcripts and, if available, a copy of your degree certificate. Photocopies and/or certified translations accepted in the first instance.
English language: if your first language is not English, please provide evidence of English Language proficiency.
Preferred start date
1st October 2012
Page last modified on 23 jul 12 16:42